2007/47/EC: why buying standards revisions can be frustrating
This article was originally published in Clinica
Manufacturers and consultants in the UK, and very likely elsewhere in the EU, who need to keep abreast with the latest standards changes may be questioning the costs of standards revised in the light of Directive 2007/47/EC which amends the medical device directives, given how minor some of the changes may be.
You may also be interested in...
What will the fall-out of political tensions between the EU and Switzerland mean for notified bodies based in Switzerland, and for the future recognition of CE marks granted in one of the most important medtech markets in Europe?
Eighteen years of free trade threatens to come to a sudden stop, as a result of the stalemate in the market access agreement between Switzerland and the EU. Industry association Swiss Medtech is advising local medtech manufacturers to find notified bodies and authorized representatives based in the EU. However, local company SQS remains confident of its ongoing notified body role.
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.